Or Pfizer can just increase the price to the high end valuation, what's $90M USD to Pfizer given the massive revenue potential for acute respiratory diagnosis (children and adult) and chronic respiratory management for Asthma (children and adult) and COPD (adult)......
No-vote letter update, page-208
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #